LEH (Libertatis Ergo Holding) advances the impact of Leiden University's activities by supporting entrepreneurs, investing in startup and spinout companies, and in entrepreneurship education programs which bring research and innovation to the market.

Investing in Science Based Startups on behalf of Leiden University

Libertatis Ergo Holding B.V.

Industry veteran Helmuth van Es joins Cantoni Therapeutics' Board of Directors

Leiden, The Netherlands, April 8, 2024. Cantoni announced its Board of Directors has been strengthened with biotech industry veteran Helmuth van Es Ph.D.

Helmuth van Es has more than 30 years of experience in life sciences as an entrepreneurial scientist and C-suite biotech executive. He was a co-founder of Galapagos and four other therapeutic biotech companies, three of which are at clinical stage and was the former CEO of Citryll developing the NETosis inhibitor to clinical proof of concept stage. A total of €125M was raised into these four startups. Helmuth continues to serve on the Citryll Board of Directors, and previously served on the boards of Antabio, Spinnovation, Audion Therapeutics and Hifibio. His therapeutic area of expertise includes rheumatoid arthritis, lupus, hidradenitis supperativa, sensorineural hearing loss, viral infections such as dengue, drug resistant bacterial infections, oncology and more.
 
“We are honoured to welcome Helmuth to the Board of Cantoni. His impressive track record in drug discovery and development adds significant value to the progression of Cantoni’s programmes”, says Managing Director of LEH, and Director of Cantoni, Rob Mayfield.
 
“Cantoni is a pioneer in the Nicotinamide N-methyltransferase (NNMT) space with best in class inhibitors in preclinical development for lipid disorders and cancer, originating from Leiden University. This is an exciting example of high quality science with the clear potential to become future medicines for patients in need. I am excited to join the Cantoni Board and support the team to help advance its lead asset into the clinic and beyond" says Helmuth van Es.

About Cantoni:
Cantoni Therapeutics B.V. is a private pharmaceutical company based in Leiden, the Netherlands that is dedicated to the development and commercialization of NNMT inhibitors. NNMT is expressed in a number of tissues including the liver and is found in other tissues such as adipocytes. NNMT is an attractive drug target for metabolic syndrome and certain cancers where it is found to be overexpressed. Elevated NNMT activity is correlated with obesity, insulin resistance and blood glucose levels as well as tumor aggressiveness and is believed to promote cancer migration, invasion, and proliferation through epigenetic changes.
 
Cantoni was founded in 2020 by Libertatis Ergo Holding B.V. (LEH) and scientific founders Dr Matthijs van Haren and Professor Nathaniel Martin, both scientists with an impressive track-record in discovery and optimization of small molecule drug candidates.
 
About LEH:
LEH is an independent seed investor in life science and health companies, which creates, supports and invests in startup and spinout companies connected to the activities of Leiden University, many of which are located on the Leiden Bio Science Park. www.libertatisergo.com

Contact: 
Rob Mayfield: r.h.mayfield@bb.leidenuniv.nl

Google Maps

Cloudflare Hosting

Google Maps API

Early Stage Venture Investors with Investments in Great Lakes

Europe Seed Stage Investors

Seed Stage Investors with Investments in Midwestern US

Early Stage Venture Investors with Investments in Rotterdam, Zuid-Holland

LEH focuses on investing in science-based startups.

Leiden

Zuid-Holland

The Netherlands

Europe

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 7, 2024 7:47 AM	9fd1f338
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	2b56fdd9
crunchbase profile	general	Oct 30, 2024 8:07 AM	399adc36
li profile	general	Aug 7, 2024 7:47 AM	3ea73edc
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	09efd33d
peers	general	Aug 7, 2024 7:47 AM	58bc0ea4
news basic	general	Aug 7, 2024 7:47 AM	b133ef2b
bundesanzeiger	filings
financials download nd	financials
private financials	financials

LIBE

COM:LIBERTATISERGO

LEH